Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma. CancerNetwork® spoke with Surbhi Sidana, MD, associate professor and hematologist of the Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and vice chair of the American Society of Hematology’s Committee on Communications, about the results from the phase 1/2 LINKER-MM1 trial (NCT03761108) published in the Journal of Clinical Oncology, in which investigators assessed the efficacy and safety of linvoseltamab in patients diagnosed with relapsed/refractory multiple myeloma.1 The interview followed the recent FDA decision to give linvoseltamab a complete response letter for this application due to a third party manufacturing site issue.

Linvoseltamab Achieves Deep and Durable Responses in R/R Multiple Myeloma

As gene editing technology continues to advance, it could fundamentally change the landscape of cancer treatment. A couple of decades ago, I was interviewing for hematology/oncology fellowships around the country. During an interview, a program director asked me a question that I had never thought about before and did not see coming. The question went something like this: “If you were the director of the National Cancer Institute and you had $3 billion to invest on 1 and only 1 area of oncology research, where would you spend it?”

The Promise of Gene Editing in Cancer Approaches Fruition

Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer. The long-time collaborators, which previously worked together to identify patients with specific lung tumors susceptible to targeted treatments, will now develop new genotyping assays based on Qiagen’s QIAstat‑Dx multiplex PCR system.

Qiagen, AstraZeneca expand companion diagnostic partnership to chronic diseases beyond cancer

The US Sun

A SCHOOLGIRL has been denied lifeline cancer therapy because NHS doctors say she’s ‘too old’ and ‘too young’. Faith Shone, 16, has leukaemia, which was caused by the heavy doses of chemotherapy she received two years ago to treat a leg tumour. Doctors say heavier doses of chemotherapy could cause her heart to fail, which […]

Teenager has to pay 70K for cancer treatment in NHS ‘blind spot’ or take offer of palliative care

Interesting Engineering

Janusz Racz, a 67-year-old lung cancer patient, is the first to receive this groundbreaking vaccine.

67-year-old receives world-first lung cancer vaccine as human trials begin

Transitional cell carcinoma (TCC) kidney cancer is a rare type of cancer that may have no symptoms at first. A person may be more at risk due to several factors, including exposure to certain substances. Transitional cell carcinoma (TCC) kidney cancer is a type of cancer in the lining of...

What to know about TCC kidney cancer

Approved a new initial treatment for advanced non-small-cell lung cancer after clinical trials showed patients lived longer without disease progression, compared to the standard treatment currently used. The chemotherapy-free combination involves two drugs, one of which has never been approved for use in the U.S. called lazertinib, which will be...

FDA Approves New Treatment for Non-Small-Cell Lung Cancer

Facilities may be the traditional setting for dialysis, but emerging home-based treatments present an opportunity to rethink kidney care. At home, patients and providers alike can enjoy benefits that dialysis clinics are unable to provide, according to Michael Aragon, MD, a nephrologist and chief medical officer at dialysis solutions firm Outset Medical.

Home-based dialysis gives patients, clinicians more treatment options, nephrologist says

North Carolina State

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Town Talks

Life expectancy in the United States has been steadily increasing, with the average lifespan rising by nearly seven years over the past half-century. According to the Centers for Disease Control and Prevention (CDC), the average lifespan was 70.8 years in 1970 and increased to 77.5 years by 2022.

These are the Counties with the longest life expectancy in North Carolina

The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]. WATCH TIME: 5 minutes. "Going upstream is very attractive...

Expanding the Potential to Treat Alzheimer Disease With RNA Therapeutics: Sharon Cohen, MD, FRCPC

Cancer Health

In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical director of thoracic, head and neck medical oncology at Fred Hutch Cancer Center, told her that a typical patient in this situation would have about nine months to live. But he also observed that she seemed remarkably strong and vital. “He said, ‘You don’t look like my normal lung cancer patient,’” said Lindsay, who had just returned from a business trip to Europe. She was 54 at the time. “He didn’t want to take away the health I had for the limited time I had to live.”

20 Years Since an EGFR Discovery, a Woman With Stage IV Lung Cancer Is Thriving

A study suggests a new way of targeting cancer by using the body's natural immune system.

Cancer vaccine hope after killer cell research

The largest glaucoma diagnosis postponement was seen in the early menopause group (3.6 years) and the smallest observed in the late menopause group (2.7 years). Photo: Schering. Click image to enlarge. Researchers at Atlanta’s Emory University recently investigated ways in which estrogen may aid in delaying development of open-angle glaucoma....

Hormone Therapy in Postmenopausal Women Linked with Later Glaucoma Diagnosis

Neurocrine Biosciences has achieved late-stage success with muscarinic M4 selective agonist in schizophrenia. Results from a phase 2 trial of the candidate schizophrenia drug, currently known as NBI-1117568, show that it met the primary trial endpoint of a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score.

Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain

Georgia State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Daily Coffee Press

According to officials with the Southern District of Georgia, two recently unsealed federal indictments have charged 23 defendants in a series of broad conspiracies involving the use of drones to smuggle methamphetamine, marijuana, and cell phones into state prisons in Georgia.

23 Defendants Charged in Federal Indictments for Drone-Smuggling Drug Operation in Georgia

Treatment with an ARPI extended overall survival (OS), with a median OS of 38.7 months in the ARPI arm vs 21.7 months in the taxane arm and 21.8 months in the physician’s choice of treatment arm. Treatment with androgen receptor pathway inhibitors (ARPIs) led to an improved treatment response...

ARPIs achieve improved treatment response in patients with mCRPC and detectable ctDNA

Maine State

The Maine Monitor

As Maine works to address its housing crisis, much of the attention is focused on the need for new development. But there’s another issue at hand: the state’s aging housing stock.

A look at Maine’s aging housing stock

San Francisco, CA

Medical News Today

A ketogenic diet, combined with a new therapy, may help starve pancreatic cancer cells and shrink tumors, a mice study has shown.

A ketogenic diet may help block the development of pancreatic cancer

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Targeted Pulse Quiz: September 1

An expert discussed ELI-002 7P, the investigational pancreatic cancer vaccine. He explained how it works and what patients can expect regarding the ongoing research. ELI-002 7P is a vaccine being developed to treat resected pancreatic cancer and offers a “new twist on an older vaccine technology,” according to Dr. Suresh Nair.

Pancreatic Cancer Vaccine Offers ‘New Twist’ on Vaccination Technology

NewsBreak

Technology Drives Biomarker Testing Rates in Precision Oncology

The knowledge gained from biomarker testing can help develop cancer prevention, diagnosis, and treatment strategies that specifically target a person’s cancer subtype. Dramatic advances in molecular...

Technology Drives Biomarker Testing Rates in Precision Oncology

Comments / 0